Offline dengan aplikasi Player FM !
After Hours: Gabapentin: A Popular and Potentially Troublesome Medicine (From the Archives)
Manage episode 422200293 series 2533879
Gabapentin has quietly become one of the most widely-prescribed drugs in America, and some say that could spell big trouble. Michael Abrams of Public Citizen explains why, as neurologist Dr. Brian Callaghan offers a counterpoint.
Subscribe to my two podcasts: “The Sharyl Attkisson Podcast” and “Full Measure After Hours.” Leave a review, subscribe and share with your friends! Support independent journalism by visiting the new Sharyl Attkisson store. Preorder Sharyl’s new book: “Follow the $Science.”
Visit SharylAttkisson.com and www.FullMeasure.news for original reporting.
Do your own research. Make up your own mind. Think for yourself.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
232 episode
Manage episode 422200293 series 2533879
Gabapentin has quietly become one of the most widely-prescribed drugs in America, and some say that could spell big trouble. Michael Abrams of Public Citizen explains why, as neurologist Dr. Brian Callaghan offers a counterpoint.
Subscribe to my two podcasts: “The Sharyl Attkisson Podcast” and “Full Measure After Hours.” Leave a review, subscribe and share with your friends! Support independent journalism by visiting the new Sharyl Attkisson store. Preorder Sharyl’s new book: “Follow the $Science.”
Visit SharylAttkisson.com and www.FullMeasure.news for original reporting.
Do your own research. Make up your own mind. Think for yourself.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
232 episode
Semua episode
×Selamat datang di Player FM!
Player FM memindai web untuk mencari podcast berkualitas tinggi untuk Anda nikmati saat ini. Ini adalah aplikasi podcast terbaik dan bekerja untuk Android, iPhone, dan web. Daftar untuk menyinkronkan langganan di seluruh perangkat.